Adverse events · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events (severe) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (severe) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Progression‐free survival ‐ not measured · people with single or solitary brain metastasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (HRQoL) · people with single or solitary brain metastasis
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Overall survival · people with single or solitary brain metastasis
Surgery plus whole brain radiotherapy (WBRT) showed no clear difference in overall survival compared with stereotactic radiosurgery plus WBRT (low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery plus WBRT (very low certainty).
1 finding from 1 review
Progression‐free survival · people with single or solitary brain metastasis
Surgery plus whole brain radiotherapy (WBRT) showed no clear difference in progression‐free survival compared with stereotactic radiosurgery plus WBRT (low certainty).
1 finding from 1 review
Overall survival · patients with asymptomatic, incurable, metastatic colorectal cancer
Delayed chemotherapy showed no clear difference in overall survival compared with immediate chemotherapy (low certainty).
1 finding from 1 review
Nausea and vomiting · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – nausea and vomiting compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Toxicity – stomatitis · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – stomatitis compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Toxicity – diarrhoea · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – diarrhoea compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Quality of life · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Progression‐free survival · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Chemotherapy compliance · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Complete clearance · people with scabies, 2 to 80 years of ageLocation: India, Pakistan
Oral ivermectin 200 μg/kg (1 to 3 doses) may leads to lower complete clearance ‐ week 1 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).
5 findings from 1 review
RR 0.65 [0.54, 0.78]
6 studies · 613 participants
Low
RR 0.91 [0.76, 1.08]
5 studies · 459 participants
Low
RR 1 [0.86, 1.16]
1 study · 80 participants
High
Show 2 more findings
Complete clearance · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan
Oral ivermectin 200 μg/kg (1 to 2 doses) showed no clear difference in complete clearance ‐ week 1 ‐ IVER 1 dose versus PER on 5… compared with topical permethrin 5% lotion (1 to 5 applications) (low certainty).
4 findings from 1 review
RR 0.7 [0.47, 1.03]
1 study · 107 participants
Low
RR 1 [0.78, 1.29]
1 study · 120 participants
Low
RR 0.97 [0.81, 1.17]
1 study · 107 participants
Moderate
Show 1 more finding
Number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus PER on 5 consecutive nights · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan
It is very uncertain whether oral ivermectin 200 μg/kg (1 to 2 doses) changes number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus… compared with topical permethrin 5% lotion (1 to 5 applications) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan
1 finding from 1 review
Complete clearance · people with scabies, 5 to 80 years of ageLocation: India
Topical ivermectin 1% lotion (1 to 3 applications) showed no clear difference in complete clearance ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (moderate certainty).
1 finding from 1 review